ORCHESTRA BIOMED HOLDINGS, INC. Financials Orchestra BioMed Holdings, Inc.
Equities
OBIO
US68572M1062
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.95 USD | +1.43% |
|
-10.81% | -45.78% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | - | - | 326.3 | 177.1 | - | - |
| Enterprise Value (EV) 1 | - | - | 326.3 | 177.1 | 177.1 | 177.1 |
| P/E ratio | -0.92 x | -0.68 x | -6.17 x | -3.15 x | -3.17 x | -3.56 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 118 x | 53.5 x | 45.5 x | 60.4 x |
| EV / Revenue | - | - | 118 x | 53.5 x | 45.5 x | 60.4 x |
| EV / EBITDA | - | - | -6.37 x | -2.81 x | -2.49 x | -3 x |
| EV / FCF | - | - | -7.06 x | -3.69 x | -3.47 x | -3.77 x |
| FCF Yield | - | - | -14.2% | -27.1% | -28.8% | -26.5% |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | - | - | 35,744 | 35,786 | - | - |
| Reference price 2 | 10.08 | 9.980 | 9.130 | 4.950 | 4.950 | 4.950 |
| Announcement Date | 11/22/22 | 3/24/23 | 3/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 3.533 | 2.76 | 3.31 | 3.896 | 2.935 |
| EBITDA 1 | - | - | -51.22 | -63 | -71 | -59 |
| EBIT 1 | - | -32.66 | -51.51 | -62.22 | -64.6 | -56.7 |
| Operating Margin | - | -924.34% | -1,866.16% | -1,880.13% | -1,658.27% | -1,931.7% |
| Earnings before Tax (EBT) 1 | - | -33.61 | -49.12 | -58.65 | -55.4 | -49.39 |
| Net income 1 | -23.01 | -35.62 | -49.12 | -58.65 | -55.4 | -49.39 |
| Net margin | - | -1,008.15% | -1,779.71% | -1,772.05% | -1,422.05% | -1,682.83% |
| EPS 2 | -10.90 | -14.60 | -1.480 | -1.570 | -1.560 | -1.390 |
| Free Cash Flow 1 | - | - | -46.2 | -48 | -51 | -47 |
| FCF margin | - | - | -1,674.09% | -1,450.37% | -1,309.2% | -1,601.36% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 11/22/22 | 3/24/23 | 3/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.103 | 1.164 | 0.915 | 0.419 | 0.262 | 0.58 | 0.603 | 1.088 | 1.097 | 0.675 |
| EBITDA 1 | - | - | - | - | -12.41 | -14.3 | -15.3 | -16.8 | -16 | - |
| EBIT 1 | -9.828 | -11.54 | -12.96 | -14.52 | -12.48 | -15.04 | -15.53 | -16.04 | -15.46 | -14.88 |
| Operating Margin | -891.02% | -991.84% | -1,415.96% | -3,466.35% | -4,763.74% | -2,593.79% | -2,575.12% | -1,474.99% | -1,409.12% | -2,204% |
| Earnings before Tax (EBT) 1 | -9.75 | -10.94 | -12.05 | -13.32 | -12.82 | -14.99 | -14.96 | -14.49 | -14.22 | -14.18 |
| Net income 1 | -9.75 | -10.94 | -12.05 | -13.32 | -12.82 | -14.99 | -14.96 | -14.49 | -14.22 | -14.18 |
| Net margin | -883.95% | -939.86% | -1,316.5% | -3,178.04% | -4,892.37% | -2,584.14% | -2,480.27% | -1,331.84% | -1,295.9% | -2,100.3% |
| EPS 2 | -3.880 | -0.4000 | -0.3500 | -0.3800 | -0.3700 | -0.4050 | -0.4000 | -0.3800 | -0.3800 | -0.4000 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/24/23 | 5/12/23 | 8/10/23 | 11/13/23 | 3/27/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -46.2 | -48 | -51 | -47 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | - | 0.08 | 1 | 1 | 1 |
| Capex / Sales | - | - | 2.83% | 30.22% | 25.67% | 34.07% |
| Announcement Date | 11/22/22 | 3/24/23 | 3/27/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
4.95
USD
Average target price
16.33
USD
Spread / Average Target
+229.97%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -45.78% | 177M | |
| +8.88% | 221B | |
| +8.68% | 186B | |
| +14.25% | 137B | |
| +28.18% | 109B | |
| +14.65% | 52.68B | |
| +4.48% | 50.86B | |
| +4.39% | 42.53B | |
| +7.00% | 37.76B | |
| +26.06% | 31.86B |
- Stock Market
- Equities
- OBIO Stock
- Financials Orchestra BioMed Holdings, Inc.